Related Experiment Video
Updated: Aug 14, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
[Reduction of the left ventricular mass in essential hypertension patients chronically treated with monotherapy]
H P Baglivo1, G Fabregues, H O Burrieza
1División Cardiología, Policlínica Bancaria, Buenos Aires, Argentina.
Insights
Essential hypertension patients treated with atenolol, enalapril, or nifedipine showed significant blood pressure and left ventricular mass reduction. These antihypertensive drugs effectively reverse cardiac remodeling in hypertensive individuals.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- Essential hypertension is a prevalent condition associated with increased cardiovascular risk.
- Left ventricular mass (LVM) is a key indicator of cardiac remodeling and a predictor of cardiovascular events.
- Current antihypertensive therapies aim to reduce blood pressure and prevent target organ damage.
Purpose:
- To evaluate the effects of single-drug antihypertensive therapy on left ventricular mass in patients with essential hypertension.
- To compare the efficacy of atenolol, enalapril maleate, and nifedipine in reducing LVM and blood pressure.
Summary:
- A 12-month study involving 104 patients with mild to moderate essential hypertension compared atenolol, enalapril, and nifedipine against a no-medication control group.
- All three drugs significantly reduced blood pressure (BP). Atenolol also reduced heart rate, while body weight remained unchanged.
- Crucially, significant reductions in left ventricular mass (LVM) and the LVM/volume ratio were observed in patients with increased LVM across all treated groups.
Impact:
- These findings demonstrate that common antihypertensive medications can reverse cardiac hypertrophy in hypertensive patients.
- The study highlights the importance of LVM assessment in managing hypertension and suggests that effective BP control leads to favorable cardiac remodeling.
- This research supports the use of atenolol, enalapril, and nifedipine for their beneficial effects on cardiac structure in hypertensive individuals.
Abstract:
Changes in left ventricular mass (LVM) were measured by echocardiography in 104 mild and moderate essential hypertensives treated with only one drug for at least 12 months. They were classified into 4 groups. G1: 40 patients (p) treated with atenolol (73.6 +/- 31.8 mg daily), G2: 32 p treated with enalapril maleate (17.7 +/- 8.7 mg daily), G3: 22 p treated with nifedipine (44.0 +/- 10.8 mg daily), G4: control group, 10 mild hypertensives without medication. At the end of the treatment blood pressure (BP) fell significantly in the first 3 groups (G1: 155 +/- 19/.98 +/- 11 vs. 136 +/- 11/86 +/- 15 mm Hg, G2: 163 +/- 19/104 +/- 10 vs. 139 +/- 12/90 +/- 8 mm Hg, G3: 166 +/- 17/103 +/- 7 vs. 142 +/- 7/85 +/- 7 mm Hg, p less than 0.001), but remained unchanged in G4. Heart rate was reduced significantly only in G1. Body weight did not change (71 +/- 7 vs. 67 +/- 7, p greater than .05). Patients were subclassified according to wether they had normal (N, LVM less than 120 g/m2 in females, LVm less than 135 g/m2 in males) or increased (H) LVM. There was a significant reduction in LVM in all H subgroups (G1 163 +/- 37 vs. 131 +/- 27 g/m2, G2: 155 +/- 19 vs. 126 +/- 21 g/m2, G3: 158 +/- 2 vs. 138 +/- 38 g/m2, p less than .005). The LVM/left ventricular end-diastolic volume ratio (M/V) fell in all H subgroups.(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Mitral Regurgitation I: Introduction
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Cardiomyopathy V: Interprofessional Care
Hypertension IV: Drug Therapy and Lifestyle Modifications